Metformin
Clifford J. Bailey, Robert C. Turner · New England Journal of Medicine · 1996
Metformin (dimethylbiguanide) is an orally administered drug used to lower blood glucose concentrations in patients with non-insulin-dependent diabetes mellitus (NIDDM).1 It improves insulin sensitivity and thus decreases the insulin resistance that is prevalent in NIDDM. The efficacy of glycemic control achieved with metformin is similar to that achieved with sulfonylureas, although their modes of action differ. Metformin can be used either as initial therapy or as an additional drug when sulfonylurea therapy alone is inadequate. In this article we shall discuss the pharmacology and clinical use of metformin, which is now available in the United States.The Burden of Non-Insulin-Dependent . . .
Cited by 1,729 works. doi:10.1056/nejm199602293340906
Authors
References
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus
- Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease
- Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study
- Banting lecture 1988. Role of insulin resistance in human disease
- Prevalence of Diabetes and Impaired Glucose Tolerance and Plasma Glucose Levels in U.S. Population Aged 20–74 Yr
- Morbidity and Mortality in Diabetics In the Framingham Population: Sixteen Year Follow-up Study
- Pathogenesis of NIDDM: A Balanced Overview
- Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
- Quantitation of Muscle Glycogen Synthesis in Normal Subjects and Subjects with Non-Insulin-Dependent Diabetes by13C Nuclear Magnetic Resonance Spectroscopy
- Mortality and survival in Type 2 (non-insulin-dependent) diabetes mellitus